Oslo, Norway, November 30, 2021 - An Extraordinary General Meeting of Vaccibody
AS was held on November 30, 2021. All proposed resolutions on the agenda were
approved in accordance with the notice for the meeting published on November 23,
Minutes of the meeting are attached hereto.
About Nykode Therapeutics (formerly Vaccibody)
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode Therapeutics' modular
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen specific
immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer